Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
823
datasets available to search
ShareScore release 0.9.0
Dataset results
823 results for “kRas”
A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT04620330. IPD Sharing: Not stated. Countries: 5. Publications: 1.
Detection of KRAS, NRAS et BRAF Mutations in Plasma Circulating DNA From Patients With Metastatic Colorectal Cancer
ClinicalTrials.gov study NCT02751177. IPD Sharing: YES. Countries: 1. Publications: 1.
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
ClinicalTrials.gov study NCT06119581. IPD Sharing: YES. Countries: 29. Publications: 0.
A Study of MEHD7945A and Cobimetinib in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS
ClinicalTrials.gov study NCT01986166. IPD Sharing: Not stated. Countries: 2. Publications: 1.
A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China
ClinicalTrials.gov study NCT05009329. IPD Sharing: NO. Countries: 1. Publications: 3.
tailOred dRug repurposIng of dEcitabine in KRAS-dependeNt refracTory pAncreaTic cancEr
ClinicalTrials.gov study NCT05360264. IPD Sharing: NO. Countries: 1. Publications: 0.
Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC)
ClinicalTrials.gov study NCT01652482. IPD Sharing: Not stated. Countries: 10. Publications: 1.
Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab
ClinicalTrials.gov study NCT05472623. IPD Sharing: NO. Countries: 1. Publications: 0.
Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies
ClinicalTrials.gov study NCT07004244. IPD Sharing: NO. Countries: 1. Publications: 13.
Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation
ClinicalTrials.gov study NCT05198934. IPD Sharing: YES. Countries: 12. Publications: 3.
FOLFOXIRI Plus Panitumumab In Kras and Braf Wild-Type Metastatic Colorectal Cancer
ClinicalTrials.gov study NCT01358812. IPD Sharing: Not stated. Countries: 1. Publications: 4.
Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected
ClinicalTrials.gov study NCT01704703. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
ClinicalTrials.gov study NCT04185883. IPD Sharing: YES. Countries: 13. Publications: 1.
A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation
ClinicalTrials.gov study NCT05756153. IPD Sharing: Not stated. Countries: 3. Publications: 0.
A Tasquinomod-loaded dopamine-modified pH sensitive hydrogel is effective at inhibiting the proliferation of KRAS mutant lung cancer cells
Open the record for dataset details and reuse information.
The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
<p>We directly interrogated the role of selected genes in mediating therapeutic response to MRTX849 utilizing a focused CRISPR/Cas9 knockout screen targeting approximately 400 genes including many genes involved in KRAS signaling. This was conducted in H358 and H2122 cells in vitro and in H2122 xenografts in vivo in presence and absence of MRTX849 treatment.</p> <p>Three independent drug anchored CRISPR studies were performed and two data files have been provided for each study. The .csv metadata files contain sample IDs, replicate number, sample descriptions and various experimental conditions. The .xlsx data files contain guide labels, guide sequences and NGS guide counts.Three independent drug anchored CRISPR studies were performed and two data files have been provided for each study. The .csv metadata files contain sample IDs, replicate number, sample descriptions and various experimental conditions. The .xlsx data files contain guide labels, guide sequences and NGS guide counts.</p>
NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy
Open the record for dataset details and reuse information.
Comments on "Current status and quality of radiomic studies for predicting KRAS mutations in colorectal cancer patients: A systematic review and meta-analysis"
Open the record for dataset details and reuse information.
Gene expression analysis of KRAS knockout pancreatic cancer cell line CFPAC1
<p>We used CRISPR to inactivate mutant KRAS in CFPAC1 (KRASG12V) pancreatic cancer cell lines. Gene expression analysis of KRAS intact vs. knockout cells identified sets of genes involved in protein synthesis, cell differentiation, and metabolic processes, while the expression of MAPK/ERK target genes remained unperturbed.</p>
Targeting Myc-driven stress vulnerability in mutant KRAS colorectal cancer (Ruan et al.)
<p>Mutant <em>KRAS </em>is a key driver in colorectal cancer (CRC) and promotes Myc translation and Myc-dependent stress adaptation and proliferation. Here, we report that the combination of two FDA-approved drugs Bortezomib and Everolimus (RAD001) (BR) is highly efficacious against mutant <em>KRAS </em>CRC cells. Mechanistically, the combination, not single agent, rapidly depletes Myc protein, not mRNA, and leads to GCN2- and p-eIF2a-dependent cell death through the activation of extrinsic and intrinsic apoptotic pathways. Cell death is selectively induced in mutant <em>KRAS </em>CRC cells with elevated basal Myc and p-eIF2a and is characterized by CHOP induction and transcriptional signatures in proteotoxicity, oxidative stress, metabolic inhibition, and immune activation. BR-induced p-GCN2/p-eIF2a elevation and cell death are strongly attenuated by <em>MYC </em>knockdown and enhanced by <em>MYC </em>overexpression. The BR combination is efficacious against mutant <em>KRAS </em>patient derived organoids (PDO) and xenografts (PDX) by inducing p-eIF2a/CHOP and cell death. Interestingly, an elevated four-gene (DDIT3, GADD45B, CRYBA4 and HSPA1L) stress signature is linked to shortened overall survival in CRC patients. These data support that Myc-dependent stress adaptation drives the progression of mutant <em>KRAS </em>CRC and serves as a therapeutic vulnerability, which can be targeted using dual translational inhibitors.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.